Janus Henderson Global Life Sciences Fund - T Shares
Janus Henderson Global Life Sciences Fund - T Shares (JAGLX)
The Janus Henderson Global Life Sciences Fund primarily focuses its investment strategy on companies operating within the life sciences field. Typically, at least 80% of its net assets (which includes any borrowed funds for investment) are allocated to firms that the portfolio manager believes exhibit a life sciences orientation. Additionally, as a fundamental investment principle, the fund generally commits a minimum of 25% of its total assets to businesses officially classified within the "life sciences" sector.
JAGLX Mutual Fund Chart & Stats
- Previous Close
- $95.59
- Sub-Category
- Global,International
- Total Liabilities
- $11.19M
- Last Dividend Ex-Date
- Dec 05, 2025
- Expense Ratio
- 0.92%
- Holding Count
- 84
- Brand
- Janus Investment Fund
- Dividend Yield
- (3.81%)
- Category
- Equity
- Total Assets
- 5.82B
- Shares Outstanding
- N/A
- 52-Week Range
- $74.88 - $95.59
JAGLX Mutual Fund News
AbbVie Crohn’s Disease Study Update Offers Limited Near-Term Stock Impact
Abbvie ($ABBV) announced an update on their ongoing clinical study. Study Overview: AbbVie’s official study, “A Post-marketing Non-interventional Study for Upadacitinib in Patients With Moderately to Severely Active Crohn’s Disease
JAGLX Mutual Fund Smart Score
Top 10 Holdings
| Name | Weight % |
|---|---|
| LLYEli Lilly And Company | 9.41% |
| JNJJohnson & Johnson | 7.09% |
| ABBVAbbvie | 4.67% |
| UNHUnitedhealth Group Inc. | 4.54% |
| AZNAstraZeneca plc | 3.93% |
| RVMDRevolution Medicines, Inc. | 3.02% |
| ARGXArgenx | 2.63% |
| NVSNovartis AG | 2.56% |
| TMOThermo Fisher Scientific | 2.33% |
| PRAXPraxis Precision Medicines, Inc. | 2.19% |
| Total | 42.37% |
Recently Viewed
No data currently available






